On August 8th, 2023, Masimo Corporation ($NASDAQ:MASI) reported their Q2 FY2023 earnings results as of June 30th, 2023. Total revenue for the second quarter was USD 455.3 million, which was a 19.5% decrease year-over-year from the same period in the previous year. Net income also decreased 13.3% to USD 15.7 million compared to the same period in FY2022.
On Tuesday, MASIMO CORPORATION reported their financial results for the second quarter of their fiscal year 2023, ending on June 30, 2023. The company’s stock opened at $122.1 and closed at $120.0, representing a 2.4% decrease from its prior closing price of $123.0. This improvement was driven by an increase in cash from operations, which was partially offset by an increase in capital expenditures and debt principal payments.
Overall, MASIMO CORPORATION reported a solid set of financial results for its fiscal year 2023 second quarter, with strong revenue growth and improved cash position driving the company’s performance. The company continues to focus on expanding its product portfolio in order to drive future growth. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Masimo Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Masimo Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Masimo Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Masimo Corporation Stock Intrinsic Value
At GoodWhale, we have conducted an analysis of MASIMO CORPORATION’s financials. Our proprietary Valuation Line has concluded that the fair value of the share of MASIMO CORPORATION is around $325.9. Taking into consideration the current market price, we observe that MASIMO CORPORATION’s stock is currently being traded at $120.0, undervalued by 63.2%. This presents a great buying opportunity for investors who are looking to make a long-term investment in the company. More…
Risk Rating Analysis
Star Chart Analysis
In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.
Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.
– Essilorluxottica ($LTS:0OMK)
EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.
– Compumedics Ltd ($ASX:CMP)
Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.
Investors should take note of the recent earnings report from Masimo Corporation for the second quarter of 2023. Total revenue was USD455.3 million, a decrease of 19.5% year-over-year. Net income also decreased 13.3% to USD15.7 million.
Short-term investors may be discouraged by the company’s declining revenue and income, however long-term investors should consider Masimo’s continued commitment to research and development, as well as their potential to capitalize on emerging technologies. Masimo is also in a competitive position due to their partnerships with multiple healthcare providers, and their ability to provide a range of innovative medical devices and therapies.